{
    "Trade/Device Name(s)": [
        "Lp(a) Ultra"
    ],
    "Submitter Information": "SENTINEL CH. S.p.A.",
    "510(k) Number": "K211058",
    "Predicate Device Reference 510(k) Number(s)": [
        "K180074"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFC"
    ],
    "Summary Letter Date": "December 22, 2022",
    "Summary Letter Received Date": "August 5, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5600"
    ],
    "Regulation Name(s)": [
        "Low-density lipoprotein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "Lipoprotein (a)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Na-heparin tube",
        "Li-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU680 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay",
        "Latex-based assay"
    ],
    "Methodologies": [
        "Quantitative immunoturbidimetric measurement",
        "Antigen-antibody reaction detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for SENTINEL CH. S.p.A. Lp(a) Ultra immunoturbidimetric assay for quantitative determination of lipoprotein (a) in human serum and plasma using Beckman Coulter AU680 analyzer",
    "Indications for Use Summary": "In vitro diagnostic immunoturbidimetric assay for quantitative determination of lipoprotein (a) in human serum and plasma, useful for evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease in specific populations, used in conjunction with clinical evaluation",
    "fda_folder": "Immunology"
}